MCL Literature Feed

This case report describes an extremely rare pancreatic collision tumor of MCL and adenocarcinoma, hypothesizing a potential role for cyclin D1 in promoting the second malignancy.

This multi-modal single-cell atlas of the human tonsil provides a high-resolution map of normal B-cell development, enabling a deeper understanding of MCL's cellular origins and heterogeneity.

In a mixed lymphoma cohort, this retrospective study found cardiac involvement in 1.5% of patients, primarily DLBCL with pericardial effusion, but provides no specific data on MCL.

This case report describes mantle cell lymphoma presenting atypically as erosive duodenitis, highlighting a rare gastrointestinal manifestation that can mimic more common inflammatory conditions.

This case report identifies a rare, leukemic, cyclin D1/SOX11-negative MCL driven by a CCND3::IGH rearrangement, highlighting a diagnostic pitfall and the importance of molecular testing in atypical cases.

SOX11 expression in cyclin D1-negative large B-cell neoplasms defines them as a variant of blastoid MCL, not DLBCL, solidifying SOX11 as a crucial diagnostic marker for aggressive MCL.

This case report describes a rare presentation of mantle cell lymphoma as a large right atrial mass, highlighting the potential for significant cardiac involvement and informing differential diagnosis.

Optical genomic mapping (OGM) identifies rare CCND1 rearrangements, securing an MCL diagnosis in atypical CD5-negative, non-nodal cases that mimic other indolent B-cell lymphomas.

A novel BRAF N581S mutation was identified in mantle cell lymphoma, expanding the known genomic landscape and suggesting a potential new therapeutic target for this rare patient subset.

This review summarizes the rare presentation of mantle cell lymphoma in the lacrimal sac, highlighting the unique diagnostic and multidisciplinary therapeutic challenges posed by this specific anatomical site.

This pathology workshop report clarifies the differential diagnosis of aggressive B-cell lymphomas, including pleomorphic MCL, by applying updated WHO-HAEM5 and ICC 2022 classifications for improved diagnostic accuracy.

The British Society for Haematology provides updated, evidence-based guidelines on MCL diagnosis, risk stratification, and treatment algorithms, standardizing care for UK patients.

A machine learning algorithm accurately classifies MCL versus other B-cell lymphomas using standard peripheral blood flow cytometry data, offering a tool to standardize and accelerate initial diagnosis.

This dual-center retrospective analysis of 20 patients with blastoid MCL characterizes its clinical features and prognosis, adding to the limited evidence base for this aggressive subtype.

This case of blastoid MCL with aberrant CD10 expression highlights a rare immunophenotype, creating a diagnostic pitfall that can mimic other aggressive B-cell lymphomas.

This case report describes a rare transformation of CD5-negative MCL into an EBV-positive pleomorphic variant, highlighting a potential role for EBV in aggressive disease progression and diagnosis.

In a large retrospective series of bilateral lacrimal gland lesions, mantle cell lymphoma was identified as a rare cause (4.4%), highlighting an uncommon extranodal presentation for clinicians.

A rare case of extranodal composite MCL and classical Hodgkin lymphoma highlights the need for comprehensive pathological workup to identify dual pathologies, which impacts treatment and relapse patterns.

This case of asymptomatic multiple lymphomatous polyposis in an elderly MCL patient demonstrates that significant GI involvement can be clinically silent, reinforcing the need for routine endoscopic staging.

This single-center retrospective study characterizes the aggressive clinical and pathological features of blastoid MCL, underscoring its diagnostic challenges and the need for novel therapeutic approaches for this high-risk subtype.

This case of lacrimal sac MCL, initially misdiagnosed as a mucocele, highlights a rare extranodal presentation requiring histopathological confirmation for accurate diagnosis in atypical periorbital masses.

This study shows ROR1 is heterogeneously expressed in 44% of MCL tumors, indicating that patient selection will be critical for developing ROR1-targeted therapies like ADCs or CAR-T.